The National Medicines Authority (Infarmed) withdrew from the market a batch of a medication used for the treatment of intestinal inflammations. The decision was made for security reasons that are not specified in the article.
The regulatory authority recommends that patients who may be using this medication contact their attending physician. The objective is to assess the need to proceed with replacement by an available alternative medication.
Users are thus advised not to abruptly stop treatment without medical supervision, in order to ensure continuity of healthcare.
